Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds

A Phase 3, Single-centered, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Morphine Sulfate Gel 0.1% in Patients With Stage 2-3 Wounds

Morphine gel applied topically to wounds will reduce wound pain and decrease patients use of oral and intravenous pain medications, therefore reducing side effects.

Patients will be randomized to receive either placebo (versa base gel) or morphine gel to wound. Patients receiving morphine gel will have a decrease in pain score and use less oral/intravenous pain medications.

Inclusion Criteria:

• Signed and dated consent form & HIPAA
• >/= 18 yo
• Single stage 2-3 wound evaluated by our wound care team
• Alert and oriented (thinking ability clear and intact, physician approval)
• English language proficiency, likely to be able to participate in all scheduled evaluations

Exclusion Criteria:

• Allergy to morphine, codeine, or versa base
• pts taking medications for acute condition, other than for the wound pain (can be taking chronic pain meds if current dose stable for past 3 mo)
• Patients with neuropathies
• Patients with respiratory conditions
• Patients that are pregnant